Free Trial
NASDAQ:CMMB

Chemomab Therapeutics Q3 2023 Earnings Report

Chemomab Therapeutics logo
$1.29 -0.07 (-5.32%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Chemomab Therapeutics EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A

Chemomab Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chemomab Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Earnings Documents

Chemomab Therapeutics Earnings Headlines

Chemomab Hikes on Q1 Figures
Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
Chemomab reports promising PSC treatment data
See More Chemomab Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB), a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

View Chemomab Therapeutics Profile

More Earnings Resources from MarketBeat